Yes we are here is some proof: Plus I'm sure they are a lot
Yes we are here is some proof: Plus I'm sure they are a lot more.
Progressive Care Announces Telehealth Partnership With EagleForce Health to Drive myVax Digital Passport for COVID-19 Testing and Vaccination
BY GlobeNewswire
— 7:00 AM ET 02/16/2021
MIAMI, FL, Feb. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Progressive Care Inc. ( RXMD
Loading...
Loading...
) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce a new partnership with EagleForce Health, LLC to integrate its proprietary telehealth platform (“myVax™”) and develop a platform for the Company’s Digital Passport for COVID-19 Testing and Vaccination results.
“The need for a digital passport to help manage our coming post-pandemic environment is paramount, and we believe myVax™ can develop into a market-leading solution to meet that need,” remarked Alan Jay Weisberg, CEO and Chairman of Progressive Care ( RXMD
Loading...
Loading...
). “This partnership will allow Progressive Care ( RXMD
Loading...
Loading...
) to expand our telehealth presence and scale more of our operations in a geographically agnostic manner through significant exposure to one of the most important opportunities defining the intermediate-term future in the business economy: digital proof of vaccination.”
The myVax™ platform is expected to launch over the coming weeks and to include complete patient scheduling, telehealth, and tele-pharmacy platform services. “Our partnership with Progressive Care ( RXMD
Loading...
Loading...
) is designed to focus on the COVID-19 digital passport roll-out to support the Company’s first line health service providers who see, touch, and bring solutions directly to the patient. Phase 1 of the myVax™ platform launch will be made available to the patient population well beyond the COVID 19 pandemic. The full scope of our commitment to this partnership will bring transformational outcomes to patient adherence and self-management of disease to the rapidly growing Telehealth marketplace. We are so proud to have Progressive Care ( RXMD
Loading...
Loading...
) as a partner,” said Stanley Campbell, CEO and Chairman of EagleForce Health, LLC.
The platform will manage an individual’s COVID-19 Vaccine and Test Journey documenting all transitions, including healthcare appointments, billing, and telehealth services. This will also include a Digital Passport or Digital Wallet that is QR-coded for registration, verification, and documentation of COVID-19 vaccination and/or test results.
This is expected to provide a powerful tool for various processes that the Company believes will come to depend upon accurate real-time virus spread risk abatement, including merchants such as cruise lines, airlines, sports venues, high-population-density, manufacturing, packing, or shipping facilities, and institutions such as school districts, universities, court proceedings, public transportation systems, and other service providers.
Mr. Weisberg added, “The COVID-19 digital passport roll-out will be our Phase 1 service launch for the myVax™ platform; however, the full scope of this partnership expands well beyond COVID-19 and is expected to powerfully augment our overall positioning in the rapidly growing Telehealth marketplace. We look forward to providing further updates and additional detail in subsequent communications.”
For more information about Progressive Care ( RXMD
Loading...
Loading...
), please visit the company’s website. Connect and stay in touch with us on social media:
Progressive Care Inc.
https://www.progressivecareus.com/
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCoRx
https://www.pharmcorx.com/get-tested-now
https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx
ClearMetrX
https://www.clearmetrx.com/
https://www.facebook.com/clearmetrx/
TOODLES
1
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
Top 5 Most Recently Viewed Articles
Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...
Continue Reading
aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...
Continue Reading
Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...
Continue Reading
GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...
Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...
Continue Reading